Add-on metformin promising in ER-positive endometrial cancer
UC Cancer Center expert comments featured in MedPage Today article
The University of Cincinnati Cancer Center's Amanda Jackson was featured in a MedPage Today article commenting on new research that found adding metformin as a combination therapy was tied to deep responses and prolonged progression-free survival in some patients with recurrent estrogen receptor (ER)-positive endometrial cancer.
All 25 patients in the RESOLVE study, led by Dana-Farber Cancer Institute, received metformin in addition to the drugs letrozole and abemaciclib.
At a median follow-up of 17 months, three patients had a complete response to the therapy, five had a partial response and 16 had stable disease. Median progression free survival was beyond 19.3 months, with no patients stopping the therapy due to toxicities.
Jackson, MD, noted multiple studies have suggested metformin can have a positive effect on progression free survival for this subset of patients.
While not effective to treat specific mutations, "metformin seems cost effective and has minimal side effects, and is probably a great option," said Jackson, a Cancer Center physician-researcher and associate professor, division chief and vice chair in the UC College of Medicine’s Department of Obstetrics & Gynecology.
Read the MedPage Today article.
Featured photo at top of hands holding a vial of metformin. Photo/Tashatuvango/iStock Photo.
Related Stories
‘GangTok’: Study provides insights about the presence of gang culture on TikTok
May 12, 2026
John Leverso, an assistant professor in the UC School of Criminal Justice, is lead author of the research, 'GangTok: Street gang content, culture, and roleplay on TikTok' published recently in Crime, Media, Culture: An International Journal.
CCM welcomes visiting arts administration faculty member Quanice G. Floyd
May 12, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of Quanice G. Floyd, EdD, as CCM's new Visiting Professor of Arts Administration. Her faculty appointment officially begins on June 1, 2026, and Floyd will work to develop and launch a new online degree in Arts Administration at CCM.
Is there anything to fear from Hantavirus?
May 12, 2026
The University of Cincinnati's Carl Fichtenbaum, MD, professor of clinical medicine in the Division of Infectious Diseases in the Department of Internal Medicine at the College of Medicine, recently appeared on Scott Sloan's show on 700 WLW to share facts surrounding Hantavirus.